Cargando…
A Case of Long QT Syndrome Type 3 Aggravated by Beta-Blockers and Alleviated by Mexiletine: The Role of Epinephrine Provocation Test
Long QT syndrome (LQTs) is an uncommon genetic disease causing sudden cardiac death with Torsade de Pointes (TdP). The first line drug treatment has been known to be β-blocker. We encountered a 15-year-old female student with LQTs who had prolonged QTc and multiple episodes of syncope or agonal resp...
Autores principales: | Park, Junbeom, Kim, Sook Kyoung, Pak, Hui-Nam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575977/ https://www.ncbi.nlm.nih.gov/pubmed/23364992 http://dx.doi.org/10.3349/ymj.2013.54.2.529 |
Ejemplares similares
-
Mexiletine shortens the QT interval in a pedigree of KCNH2 related long QT syndrome
por: Fujisawa, Taishi, et al.
Publicado: (2020) -
Mexiletine infusion challenge test for neonatal long QT syndrome with 2:1 atrioventricular block
por: Okuwaki, Hajime, et al.
Publicado: (2019) -
Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3
por: Mazzanti, Andrea, et al.
Publicado: (2016) -
Effects of Mexiletine on a Race-specific Mutation in Na(v)1.5 Associated With Long QT Syndrome
por: Wu, Xin, et al.
Publicado: (2022) -
The Role of the Epinephrine Test in the Diagnosis and Management of Children Suspected of Having Congenital Long QT Syndrome
por: Clur, Sally-Ann B., et al.
Publicado: (2009)